Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

Cell Reports

Volumn 23, Issue 1, 2018, Pages 239-254.e6

  Knijnenburg, Theo A ^a   Wang, Linghua ^b,h,s   Zimmermann, Michael T ^c,r   Chambwe, Nyasha ^a,s   Gao, Galen F ^d,s   Cherniack, Andrew D ^d,s   Fan, Huihui ^e,s   Shen, Hui ^e,s   Way, Gregory P ^f   Greene, Casey S ^f   Liu, Yuexin ^b,s   Akbani, Rehan ^b,s   Feng, Bin ^g   Donehower, Lawrence A ^h,s   Miller, Chase ^h   Shen, Yang ⁱ   Karimi, Mostafa ⁱ   Chen, Haoran ⁱ   Kim, Pora ^j   Jia, Peilin ^j   Shinbrot, Eve ^h,s   Zhang, Shaojun ^b   Liu, Jia ^s   Hu, Hai ^k,s   Bailey, Matthew H ^l   Yau, Christina ^m,n,s   Wolf, Denise ^m   Zhao, Zhongming ^j   Weinstein, John N ^b,s   Li, Lei ^b   Ding, Li ^l,o,p,s   Mills, Gordon B ^b,s   Laird, Peter W ^e,s   Wheeler, David A ^h,s   Shmulevich, Ilya ^a,s   Caesar Johnson, Samantha J ^s   Demchok, John A ^s   Felau, Ina ^s   Kasapi, Melpomeni ^s   Ferguson, Martin L ^s   Hutter, Carolyn M ^s   Sofia, Heidi J ^s   Tarnuzzer, Roy ^s   Wang, Zhining ^s   Yang, Liming ^s   Zenklusen, Jean C ^s   Monnat, Raymond J ^q   Xiao, Yonghong ^g   Wang, Chen ^r   more..

^a INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e VAN ANDEL RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g TESARO   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ Department of Electrical and Computer Engineering   (United States)

^j UNIVERSITY OF TEXAS   (United States)

^k Chan Soon Shiong Institute of Molecular Medicine   (United States)

^l WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^o WASHINGTON UNIVERSITY   (United States)

^p Washington University in St Louis School of Medicine   (United States)

^q UNIVERSITY OF WASHINGTON   (United States)

^r Mayo Clinic College of Medicine   (United States)

^s Julia)

more..

Author keywords

DNA damage footprints; DNA damage repair; epigenetic silencing; integrative statistical analysis; mutational signatures; protein structure analysis; somatic copy number alterations; somatic mutations; The Cancer Genome Atlas PanCanAtlas project

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EXONUCLEASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER GROWTH; CANCER RISK; CANCER THERAPY; CLINICAL OUTCOME; DNA DAMAGE; DNA REPAIR; GENE SILENCING; GENOMICS; HETEROZYGOSITY LOSS; HOMOLOGOUS RECOMBINATION; HUMAN; MACHINE LEARNING; OVARY CANCER; PRIORITY JOURNAL; SOMATIC MUTATION; TREATMENT RESPONSE; CLASSIFICATION; GENETICS; HUMAN GENOME; METABOLISM; MUTATION; NEOPLASM; RECOMBINATION REPAIR; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA DAMAGE; GENE SILENCING; GENOME, HUMAN; HUMANS; LOSS OF HETEROZYGOSITY; MACHINE LEARNING; MUTATION; NEOPLASMS; RECOMBINATIONAL DNA REPAIR; TUMOR SUPPRESSOR PROTEINS;

EID: 85044676615     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2018.03.076     Document Type: Article

References (123)

1. Abkevich, V., Timms, K.M., Hennessy, B.T., Potter, J., Carey, M.S., Meyer, L.A., Smith-McCune, K., Broaddus, R., Lu, K.H., Chen, J., et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br. J. Cancer 107 (2012), 1776–1782.
2. Adzhubei, I., Jordan, D.M., Sunyaev, S.R., Predicting functional effect of human missense mutations using PolyPhen-2. In Curr. Protoc. Hum. Genet, Chapter 7, 2013 (John Wiley & Sons).
3. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A.J.R., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Børresen-Dale, A.-L., et al. Australian Pancreatic Cancer Genome Initiative ICGC Breast Cancer Consortium ICGC MMML-Seq Consortium, ICGC PedBrain. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
4. Aravind, L., Walker, D.R., Koonin, E.V., Conserved domains in DNA repair proteins and evolution of repair systems. Nucleic Acids Res. 27 (1999), 1223–1242.
5. Bailey, M.H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M.C., Kim, J., Reardon, B., et al. Comprehensive characterization of cancer driver genes and mutations. Cell, 173, 2018, 10.1016/j.cell.2018.02.060.
6. Balachandran, V.P., Łuksza, M., Zhao, J.N., Makarov, V., Moral, J.A., Remark, R., Herbst, B., Askan, G., Bhanot, U., Senbabaoglu, Y., et al. Australian Pancreatic Cancer Genome Initiative Garvan Institute of Medical Research Prince of Wales Hospital Royal North Shore Hospital University of Glasgow St Vincent's Hospital QIMR Berghofer Medical Research Institute University of Melbourne, Centre for Cancer Research University of Queensland, Institute for Molecular Bioscience Bankstown Hospital Liverpool Hospital Royal Prince Alfred Hospital, Chris O'Brien Lifehouse Westmead Hospital Fremantle Hospital St John of God Healthcare Royal Adelaide Hospital Flinders Medical Centre Envoi Pathology Princess Alexandria Hospital Austin Hospital Johns Hopkins Medical Institutes, ARC-Net Centre for Applied Research on Cancer. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551 (2017), 512–516.
7. Barbari, S.R., Shcherbakova, P.V., Replicative DNA polymerase defects in human cancers: Consequences, mechanisms, and implications for therapy. DNA Repair (Amst.) 56 (2017), 16–25.
8. Bartkova, J., Horejsí Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J.M., Lukas, C., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434 (2005), 864–870.
9. Bell, J.C., Kowalczykowski, S.C., Mechanics and single-molecule interrogation of DNA recombination. Annu. Rev. Biochem. 85 (2016), 193–226.
10. Bellido, F., Pineda, M., Aiza, G., Valdés-Mas, R., Navarro, M., Puente, D.A., Pons, T., González, S., Iglesias, S., Darder, E., et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet. Med. 18 (2016), 325–332.
11. Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N., Bourne, P.E., The Protein Data Bank. Nucleic Acids Res. 28 (2000), 235–242.
12. Birkbak, N.J., Wang, Z.C., Kim, J.-Y., Eklund, A.C., Li, Q., Tian, R., Bowman-Colin, C., Li, Y., Greene-Colozzi, A., Iglehart, J.D., et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2 (2012), 366–375.
13. Bocquet, N., Bizard, A.H., Abdulrahman, W., Larsen, N.B., Faty, M., Cavadini, S., Bunker, R.D., Kowalczykowski, S.C., Cejka, P., Hickson, I.D., Thomä N.H., Structural and mechanistic insight into Holliday-junction dissolution by topoisomerase IIIα and RMI1. Nat. Struct. Mol. Biol. 21 (2014), 261–268.
14. Bouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Byrnes, G., Zavadil, J., Olivier, M., TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum. Mutat. 37 (2016), 865–876.
15. Brat, D.J., Verhaak, R.G., Aldape, K.D., Yung, W.K., Salama, S.R., Cooper, L.A., Rheinbay, E., Miller, C.R., Vitucci, M., Morozova, O., et al., Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372 (2015), 2481–2498.
16. Briggs, S., Tomlinson, I., Germline and somatic polymerase ε and δ mutations define a new class of hypermutated colorectal and endometrial cancers. J. Pathol. 230 (2013), 148–153.
17. Brown, J.S., O'Carrigan, B., Jackson, S.P., Yap, T.A., Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discov. 7 (2017), 20–37.
18. Bryant, H.E., Schultz, N., Thomas, H.D., Parker, K.M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N.J., Helleday, T., Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005), 913–917.
19. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 (2012), 330–337.
20. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513 (2014), 202–209.
21. Carter, S.L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P.W., Onofrio, R.C., Winckler, W., Weir, B.A., et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30 (2012), 413–421.
22. Chen, C.-L., Rappailles, A., Duquenne, L., Huvet, M., Guilbaud, G., Farinelli, L., Audit, B., d'Aubenton-Carafa, Y., Arneodo, A., Hyrien, O., Thermes, C., Impact of replication timing on non-CpG and CpG substitution rates in mammalian genomes. Genome Res. 20 (2010), 447–457.
23. Chun, S., Fay, J.C., Identification of deleterious mutations within three human genomes. Genome Res. 19 (2009), 1553–1561.
24. Church, D.N., Briggs, S.E.W., Palles, C., Domingo, E., Kearsey, S.J., Grimes, J.M., Gorman, M., Martin, L., Howarth, K.M., Hodgson, S.V., et al., NSECG Collaborators. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer. Hum. Mol. Genet. 22 (2013), 2820–2828.
25. Ciriello, G., Miller, M.L., Aksoy, B.A., Senbabaoglu, Y., Schultz, N., Sander, C., Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45 (2013), 1127–1133.
26. Collado-Torres, L., Nellore, A., Kammers, K., Ellis, S.E., Taub, M.A., Hansen, K.D., Jaffe, A.E., Langmead, B., Leek, J.T., Reproducible RNA-seq analysis using recount2. Nat. Biotechnol. 35 (2017), 319–321.
27. Covington, K., Shinbrot, E., Wheeler, D.A., Mutation signatures reveal biological processes in human cancer. bioRxiv, 2014, 10.1101/036541.
28. Dees, N.D., Zhang, Q., Kandoth, C., Wendl, M.C., Schierding, W., Koboldt, D.C., Mooney, T.B., Callaway, M.B., Dooling, D., Mardis, E.R., et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res. 22 (2012), 1589–1598.
29. Duxin, J.P., Walter, J.C., What is the DNA repair defect underlying Fanconi anemia?. Curr. Opin. Cell Biol. 37 (2015), 49–60.
30. Eisen, J.A., Hanawalt, P.C., A phylogenomic study of DNA repair genes, proteins, and processes. Mutat. Res. 435 (1999), 171–213.
31. Esteller, M., Hamilton, S.R., Burger, P.C., Baylin, S.B., Herman, J.G., Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59 (1999), 793–797.
32. Esteller, M., Silva, J.M., Dominguez, G., Bonilla, F., Matias-Guiu, X., Lerma, E., Bussaglia, E., Prat, J., Harkes, I.C., Repasky, E.A., et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 92 (2000), 564–569.
33. Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005), 917–921.
34. Fischer, M., Census and evaluation of p53 target genes. Oncogene 36 (2017), 3943–3956.
35. Forbes, S.A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., Cole, C.G., Ward, S., Dawson, E., Ponting, L., et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 45:D1 (2017), D777–D783.
36. Friedberg, E.C., Walker, G.C., Siede, W., Wood, R.D., Schultz, R.A., Ellenberger, T., DNA Repair and Mutagenesis. Second Edition, 2004, ASM Press.
37. Garraway, L.A., Lander, E.S., Lessons from the cancer genome. Cell 153 (2013), 17–37.
38. Germano, G., Lamba, S., Rospo, G., Barault, L., Magrì A., Maione, F., Russo, M., Crisafulli, G., Bartolini, A., Lerda, G., et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552 (2017), 116–120.
39. Gingras, M.-C., Covington, K.R., Chang, D.K., Donehower, L.A., Gill, A.J., Ittmann, M.M., Creighton, C.J., Johns, A.L., Shinbrot, E., Dewal, N., et al., Australian Pancreatic Cancer Genome Initiative. Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation. Cell Rep. 14 (2016), 907–919.
40. Gobbi, A., Iorio, F., Dawson, K.J., Wedge, D.C., Tamborero, D., Alexandrov, L.B., Lopez-Bigas, N., Garnett, M.J., Jurman, G., Saez-Rodriguez, J., Fast randomization of large genomic datasets while preserving alteration counts. Bioinformatics 30 (2014), i617–i623.
41. Gorgoulis, V.G., Vassiliou, L.-V.F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., Ditullio, R.A. Jr., Kastrinakis, N.G., Levy, B., et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434 (2005), 907–913.
42. Grant, B.J., Rodrigues, A.P.C., ElSawy, K.M., McCammon, J.A., Caves, L.S.D., Bio3d: an R package for the comparative analysis of protein structures. Bioinformatics 22 (2006), 2695–2696.
43. Guintivano, J., Aryee, M.J., Kaminsky, Z.A., A cell epigenotype specific model for the correction of brain cellular heterogeneity bias and its application to age, brain region and major depression. Epigenetics 8 (2013), 290–302.
44. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
45. He, Y., Yan, C., Fang, J., Inouye, C., Tjian, R., Ivanov, I., Nogales, E., Near-atomic resolution visualization of human transcription promoter opening. Nature 533 (2016), 359–365.
46. Helleday, T., Eshtad, S., Nik-Zainal, S., Mechanisms underlying mutational signatures in human cancers. Nat. Rev. Genet. 15 (2014), 585–598.
47. Hinoue, T., Weisenberger, D.J., Lange, C.P.E., Shen, H., Byun, H.-M., Van Den Berg, D., Malik, S., Pan, F., Noushmehr, H., van Dijk, C.M., et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 22 (2012), 271–282.
48. Hogg, M., Osterman, P., Bylund, G.O., Ganai, R.A., Lundström, E.-B., Sauer-Eriksson, A.E., Johansson, E., Structural basis for processive DNA synthesis by yeast DNA polymerase ɛ. Nat. Struct. & Mol. Biol. 21 (2014), 49–55.
49. Humphrey, W., Dalke, A., Schulten, K., VMD: visual molecular dynamics. J. Mol. Graph. 14 (1996), 33–38.
50. Ionov, Y., Peinado, M.A., Malkhosyan, S., Shibata, D., Perucho, M., Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363 (1993), 558–561.
51. Jeggo, P.A., Pearl, L.H., Carr, A.M., DNA repair, genome stability and cancer: a historical perspective. Nat. Rev. Cancer 16 (2016), 35–42.
52. Kaelin, W.G.J. Jr., The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5 (2005), 689–698.
53. Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., Shen, H., Robertson, A.G., Pashtan, I., Shen, R., Benz, C.C., et al., Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 497 (2013), 67–73.
54. Kass, E.M., Moynahan, M.E., Jasin, M., When genome maintenance goes badly awry. Mol. Cell 62 (2016), 777–787.
55. Kastenhuber, E.R., Lowe, S.W., Putting p53 in context. Cell 170 (2017), 1062–1078.
56. Knijnenburg, T.A., Wessels, L.F.A., Reinders, M.J.T., Shmulevich, I., Fewer permutations, more accurate P-values. Bioinformatics 25 (2009), i161–i168.
57. Knijnenburg, T.A., Lin, J., Rovira, H., Boyle, J., Shmulevich, I., EPEPT: a web service for enhanced P-value estimation in permutation tests. BMC Bioinformatics, 12, 2011, 411.
58. Kowalczykowski, S.C., An overview of the molecular mechanisms of recombinational DNA repair. Cold Spring Harb. Perspect. Biol., 7, 2015, a016410.
59. Kuismanen, S.A., Holmberg, M.T., Salovaara, R., de la Chapelle, A., Peltomäki, P., Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am. J. Pathol. 156 (2000), 1773–1779.
60. Kumar, P., Henikoff, S., Ng, P.C., Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4 (2009), 1073–1081.
61. Lawrence, M.S., Stojanov, P., Mermel, C.H., Robinson, J.T., Garraway, L.A., Golub, T.R., Meyerson, M., Gabriel, S.B., Lander, E.S., Getz, G., Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505 (2014), 495–501.
62. Le, D.T., Durham, J.N., Smith, K.N., Wang, H., Bartlett, B.R., Aulakh, L.K., Lu, S., Kemberling, H., Wilt, C., Luber, B.S., et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357 (2017), 409–413.
63. Lee, M., Lee, K., Yu, N., Jang, I., Choi, I., Kim, P., Jang, Y.E., Kim, B., Kim, S., Lee, B., et al. ChimerDB 3.0: an enhanced database for fusion genes from cancer transcriptome and literature data mining. Nucleic Acids Res. 45:D1 (2017), D784–D789.
64. Leroy, B., Girard, L., Hollestelle, A., Minna, J.D., Gazdar, A.F., Soussi, T., Analysis of TP53 mutation status in human cancer cell lines: a reassessment. Hum. Mutat. 35 (2014), 756–765.
65. Lhotska, H., Zemanova, Z., Cechova, H., Ransdorfova, S., Lizcova, L., Kramar, F., Krejcik, Z., Svobodova, K., Bystricka, D., Hrabal, P., et al. Genetic and epigenetic characterization of low-grade gliomas reveals frequent methylation of the MLH3 gene. Genes Chromosomomes Cancer 54 (2015), 655–667.
66. Liu, J., Lichtenberg, T., Hoadley, K.A., Poisson, L.M., Lazar, A.J., Cherniack, A.D., Kovatich, A.J., Benz, C.C., Levine, D.A., Lee, A.V., et al. An integrated TCGA pan-cancer clinical data resource to drive high quality survival outcome analytics. Cell, 173, 2018, 10.1016/j.cell.2018.02.052.
67. Lord, C.J., Ashworth, A., PARP inhibitors: synthetic lethality in the clinic. Science 355 (2017), 1152–1158.
68. Macheret, M., Halazonetis, T.D., DNA replication stress as a hallmark of cancer. Annu. Rev. Pathol. 10 (2015), 425–448.
69. Mackerell, A.D. Jr., Feig, M., Brooks, C.L. 3rd, Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. J. Comput. Chem. 25 (2004), 1400–1415.
70. Marquard, A.M., Eklund, A.C., Joshi, T., Krzystanek, M., Favero, F., Wang, Z.C., Richardson, A.L., Silver, D.P., Szallasi, Z., Birkbak, N.J., Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark. Res., 3, 2015, 9.
71. Martincorena, I., Campbell, P.J., Somatic mutation in cancer and normal cells. Science 349 (2015), 1483–1489.
72. Mermel, C.H., Schumacher, S.E., Hill, B., Meyerson, M.L., Beroukhim, R., Getz, G., GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol., 12, 2011, R41.
73. Michl, J., Zimmer, J., Tarsounas, M., Interplay between Fanconi anemia and homologous recombination pathways in genome integrity. EMBO J. 35 (2016), 909–923.
74. Mills, G.B., Timms, K.M., Reid, J.E., Gutin, A.S., Krivak, T.C., Hennessy, B., Paul, J., Brown, R., Lanchbury, J.S., Stronach, E.A., Homologous recombination deficiency score shows superior association with outcome compared with its individual score components in platinum-treated serous ovarian cancer. Gynecol. Oncol. 141 (2016), 2–3.
75. Moinova, H.R., Chen, W.-D., Shen, L., Smiraglia, D., Olechnowicz, J., Ravi, L., Kasturi, L., Myeroff, L., Plass, C., Parsons, R., et al. HLTF gene silencing in human colon cancer. Proc. Natl. Acad. Sci. USA 99 (2002), 4562–4567.
76. Mozaffari-Jovin, S., Wandersleben, T., Santos, K.F., Will, C.L., Lührmann, R., Wahl, M.C., Inhibition of RNA helicase Brr2 by the C-terminal tail of the spliceosomal protein Prp8. Sci. 341 (2013), 80–84.
77. Mularoni, L., Sabarinathan, R., Deu-Pons, J., Gonzalez-Perez, A., López-Bigas, N., OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations. Genome Biol., 17, 2016, 128.
78. Newman, J.A., Savitsky, P., Allerston, C.K., Bizard, A.H., Özer, Ö., Sarlós, K., Liu, Y., Pardon, E., Steyaert, J., Hickson, I.D., Gileadi, O., Crystal structure of the Bloom's syndrome helicase indicates a role for the HRDC domain in conformational changes. Nucleic Acids Res. 43 (2015), 5221–5235.
79. Olivier, M., Hollstein, M., Hainaut, P., TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol., 2, 2010, a001008.
80. Pearl, L.H., Schierz, A.C., Ward, S.E., Al-Lazikani, B., Pearl, F.M.G., Therapeutic opportunities within the DNA damage response. Nat. Rev. Cancer 15 (2015), 166–180.
81. Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O., Blondel, M., Prettenhofer, P., Weiss, R., Dubourg, V., Scikit-learn: machine learning in Python. J. Mach. Learn. Res. 12 (2010), 2825–2830.
82. Pfister, N.T., Prives, C., Transcriptional regulation by wild-type and cancer-related mutant forms of p53. Cold Spring Harb. Perspect. Med., 7, 2017, a026054.
83. Phillips, J.C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R.D., Kalé L., Schulten, K., Scalable molecular dynamics with NAMD. J. Comput. Chem. 26 (2005), 1781–1802.
84. Pitroda, S.P., Pashtan, I.M., Logan, H.L., Budke, B., Darga, T.E., Weichselbaum, R.R., Connell, P.P., DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy. Sci. Transl. Med., 6, 2014, 229ra42.
85. Popova, T., Manié E., Rieunier, G., Caux-Moncoutier, V., Tirapo, C., Dubois, T., Delattre, O., Sigal-Zafrani, B., Bollet, M., Longy, M., et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 72 (2012), 5454–5462.
86. Ray Chaudhuri, A., Callen, E., Ding, X., Gogola, E., Duarte, A.A., Lee, J.-E., Wong, N., Lafarga, V., Calvo, J.A., Panzarino, N.J., et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature 535 (2016), 382–387.
87. Reinius, L.E., Acevedo, N., Joerink, M., Pershagen, G., Dahlén, S.-E., Greco, D., Söderhäll, C., Scheynius, A., Kere, J., Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. PLoS ONE, 7, 2012, e41361.
88. Reva, B., Antipin, Y., Sander, C., Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res., 39, 2011, e118.
89. Rogozin, I.B., Pavlov, Y.I., Goncearenco, A., De, S., Lada, A.G., Poliakov, E., Panchenko, A.R., Cooper, D.N., Mutational signatures and mutable motifs in cancer genomes. Brief. Bioinform., 2017, 10.1093/bib/bbx049.
90. Rondinelli, B., Gogola, E., Yücel, H., Duarte, A.A., van de Ven, M., van der Sluijs, R., Konstantinopoulos, P.A., Jonkers, J., Ceccaldi, R., Rottenberg, S., D'Andrea, A.D., EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat. Cell Biol. 19 (2017), 1371–1378.
91. Roy, A., Kucukural, A., Zhang, Y., I-TASSER: a unified platform for automated protein structure and function prediction. Nat. Protoc. 5 (2010), 725–738.
92. Sato, Y., Yoshizato, T., Shiraishi, Y., Maekawa, S., Okuno, Y., Kamura, T., Shimamura, T., Sato-Otsubo, A., Nagae, G., Suzuki, H., et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 45 (2013), 860–867.
93. Schwarz, J.M., Cooper, D.N., Schuelke, M., Seelow, D., MutationTaster2: mutation prediction for the deep-sequencing age. Nat. Methods 11 (2014), 361–362.
94. Schymkowitz, J., Borg, J., Stricher, F., Nys, R., Rousseau, F., Serrano, L., The FoldX web server: an online force field. Nucleic Acids Res., 33, 2005 W382-8.
95. Sherr, C.J., The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2 (2001), 731–737.
96. Shinbrot, E., Henninger, E.E., Weinhold, N., Covington, K.R., Göksenin, A.Y., Schultz, N., Chao, H., Doddapaneni, H., Muzny, D.M., Gibbs, R.A., et al. Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication. Genome Res. 24 (2014), 1740–1750.
97. Simpkins, S.B., Bocker, T., Swisher, E.M., Mutch, D.G., Gersell, D.J., Kovatich, A.J., Palazzo, J.P., Fishel, R., Goodfellow, P.J., MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum. Mol. Genet. 8 (1999), 661–666.
98. Soll, J.M., Sobol, R.W., Mosammaparast, N., Regulation of DNA alkylation damage repair: lessons and therapeutic opportunities. Trends Biochem. Sci. 42 (2017), 206–218.
99. Sparks, J.L., Kumar, R., Singh, M., Wold, M.S., Pandita, T.K., Burgers, P.M., Human exonuclease 5 is a novel sliding exonuclease required for genome stability. J. Biol. Chem. 287 (2012), 42773–42783.
100. Srivas, R., Shen, J.P., Yang, C.C., Sun, S.M., Li, J., Gross, A.M., Jensen, J., Licon, K., Bojorquez-Gomez, A., Klepper, K., et al. A network of conserved synthetic lethal interactions for exploration of precision cancer therapy. Mol. Cell 63 (2016), 514–525.
101. Stracquadanio, G., Wang, X., Wallace, M.D., Grawenda, A.M., Zhang, P., Hewitt, J., Zeron-Medina, J., Castro-Giner, F., Tomlinson, I.P., Goding, C.R., et al. The importance of p53 pathway genetics in inherited and somatic cancer genomes. Nat. Rev. Cancer 16 (2016), 251–265.
102. Sulkowski, P.L., Corso, C.D., Robinson, N.D., Scanlon, S.E., Purshouse, K.R., Bai, H., Liu, Y., Sundaram, R.K., Hegan, D.C., Fons, N.R., et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci. Transl. Med., 9, 2017, 10.1126/scitranslmed.aal2463.
103. Swan, M.K., Johnson, R.E., Prakash, L., Prakash, S., Aggarwal, A.K., Structural basis of high-fidelity DNA synthesis by yeast DNA polymerase delta. Nat. Struct. & Mol. Biol. 16 (2009), 979–986.
104. Szklarczyk, D., Morris, J.H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N.T., Roth, A., Bork, P., et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 45:D1 (2017), D362–D368.
105. Taglialatela, A., Alvarez, S., Leuzzi, G., Sannino, V., Ranjha, L., Huang, J.-W., Madubata, C., Anand, R., Levy, B., Rabadan, R., et al. Restoration of replication fork stability in BRCA1- and BRCA2-deficient cells by inactivation of SNF2-family fork remodelers. Mol. Cell 68 (2017), 414–430.e8.
106. Taylor, A.M., Shih, J., Ha, G., Gao, G.F., Zhang, X., Berger, A.C., Schumacher, S.E., Wang, C., Hu, H., Liu, J., Lazar, A.J. The Cancer Genome Atlas Research Network, Cherniack, A.D., Beroukhim, R., Meyerson, M., Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell, 33, 2018, 10.1016/j.ccell.2018.03.007.
107. Telli, M.L., Timms, K.M., Reid, J., Hennessy, B., Mills, G.B., Jensen, K.C., Szallasi, Z., Barry, W.T., Winer, E.P., Tung, N.M., et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin. Cancer Res. 22 (2016), 3764–3773.
108. Thibodeau, S.N., Bren, G., Schaid, D., Microsatellite instability in cancer of the proximal colon. Science 260 (1993), 816–819.
109. Tokheim, C.J., Papadopoulos, N., Kinzler, K.W., Vogelstein, B., Karchin, R., Evaluating the evaluation of cancer driver genes. Proc. Natl. Acad. Sci. USA 113 (2016), 14330–14335.
110. Totoki, Y., Tatsuno, K., Covington, K.R., Ueda, H., Creighton, C.J., Kato, M., Tsuji, S., Donehower, L.A., Slagle, B.L., Nakamura, H., et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat. Genet. 46 (2014), 1267–1273.
111. Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J.G., Baylin, S.B., Issa, J.P., CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA 96 (1999), 8681–8686.
112. Tubbs, A., Nussenzweig, A., Endogenous DNA damage as a source of genomic instability in cancer. Cell 168 (2017), 644–656.
113. Van Durme, J., Delgado, J., Stricher, F., Serrano, L., Schymkowitz, J., Rousseau, F., A graphical interface for the FoldX forcefield. Bioinforma 27 (2011), 1711–1712.
114. Wang, P., Wu, J., Ma, S., Zhang, L., Yao, J., Hoadley, K.A., Wilkerson, M.D., Perou, C.M., Guan, K.-L., Ye, D., Xiong, Y., Oncometabolite D-2-hydroxyglutarate inhibits ALKBH DNA repair enzymes and sensitizes IDH mutant cells to alkylating agents. Cell Rep. 13 (2015), 2353–2361.
115. Watkins, J.A., Irshad, S., Grigoriadis, A., Tutt, A.N.J., Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res., 16, 2014, 211.
116. Way, G.P., Sanchez-Vega, F., La, K., Armenia, J., Chatila, W.K., Luna, A., Sander, C., Cherniack, A.D., Mina, M., Ciriello, G., et al. Pan-cancer Ras pathway activation in The Cancer Genome Atlas. Cell Rep., 23, 2018, 10.1016/j.celrep.2018.03.046.
117. Weller, M., Tabatabai, G., Kästner, B., Felsberg, J., Steinbach, J.P., Wick, A., Schnell, O., Hau, P., Herrlinger, U., Sabel, M.C., et al., DIRECTOR Study Group. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the director trial. Clin. Cancer Res. 21 (2015), 2057–2064.
118. Yoshihara, K., Wang, Q., Torres-Garcia, W., Zheng, S., Vegesna, R., Kim, H., Verhaak, R.G., The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene 34 (2015), 4845–4854.
119. Yue, F., Cheng, Y., Breschi, A., Vierstra, J., Wu, W., Ryba, T., Sandstrom, R., Ma, Z., Davis, C., Pope, B.D., et al., Mouse ENCODE Consortium. A comparative encyclopedia of DNA elements in the mouse genome. Nature 515 (2014), 355–364.
120. Zack, T.I., Schumacher, S.E., Carter, S.L., Cherniack, A.D., Saksena, G., Tabak, B., Lawrence, M.S., Zhsng, C.-Z., Wala, J., Mermel, C.H., et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45 (2013), 1134–1140.
121. Zahn, K.E., Averill, A.M., Aller, P., Wood, R.D., Doublié S., Human DNA polymerase θ grasps the primer terminus to mediate DNA repair. Nat. Struct. & Mol. Biol. 22 (2015), 304–311.
122. Zeman, M.K., Cimprich, K.A., Causes and consequences of replication stress. Nat. Cell Biol. 16 (2014), 2–9.
123. Zimmermann, M.T., Jiang, G., Wang, C., Single-sample expression-based chemo-sensitivity score improves survival associations independently from genomic mutations for ovarian cancer patients. AMIA Jt. Summits Transl. Sci. Proc., 2016, 94–100.